A phase I study of ATRA combined with gemcitabine/nab-paclitaxel showed promising activity, which is currently being further evaluated in a randomised phase II trial as part of Precision-Panc, the national therapeutic development platform for pancreatic cancer in the UK, with stromal-specific retinoid transport protein expression (FABP5, CRABP2) as putative predictive biomarkers [139,142,143] (Figure 4). This evidence concerns the gene FABP5 and pancreatic neoplasm.